Literature DB >> 15531547

Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome.

Sabine E Hannema1, Ian S Scott, John Hodapp, Howard Martin, Nick Coleman, John W Schwabe, Ieuan A Hughes.   

Abstract

Development of the Wolffian ducts (WD) into epididymides and vasa deferentia is dependent on testosterone. Patients with the complete androgen insensitivity syndrome (CAIS) are therefore not expected to develop these structures. However, WD derivatives have been described in cases of CAIS. It is thought that these may be remnants. This study assesses the degree of WD development in 33 patients with CAIS and investigates whether this development was androgen dependent. Epididymides and vasa deferentia were identified in 70% of patients with substitution mutations in the androgen receptor ligand-binding domain. They were more developed than epididymides and vasa deferentia from 16- to 20-wk-old male fetuses, suggesting that the WD had been stimulated to grow, rather than failed to regress. Receptors with substitutions in the ligand-binding domain were normally expressed and showed residual response to androgens in transactivation assays. Patients with premature stop codons or frameshift mutations, which prevented androgen receptor expression, or DNA-binding domain mutations that abolished transcriptional activity did not have epididymides or vasa deferentia. We hypothesize that mutant receptors with residual activity in vitro respond to high local testosterone concentrations in vivo, thereby stimulating WD development. The classification of androgen insensitivity in such patients should be considered severe rather than complete.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531547     DOI: 10.1210/jc.2004-0709

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.

Authors:  Christine Helsen; Vanessa Dubois; Annelien Verfaillie; Jacques Young; Mieke Trekels; Renée Vancraenenbroeck; Marc De Maeyer; Frank Claessens
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  Clinical and genetic characterization of six cases with complete androgen insensitivity syndrome in China.

Authors:  Jing He; Shuwu Qi; Huijun Zhang; Jingjing Guo; Shu Chen; Qi Zhang; Baosheng Zhu
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

Review 3.  [Psychosexual aspects of intersex syndromes].

Authors:  H A G Bosinski
Journal:  Urologe A       Date:  2006-08       Impact factor: 0.639

4.  Characterization of androgen receptor structure and nucleocytoplasmic shuttling of the rice field eel.

Authors:  Fang Zhou; Wei Zhao; Zhixiang Zuo; Yue Sheng; Xiang Zhou; Yu Hou; Hanhua Cheng; Rongjia Zhou
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

5.  A hotspot in the glucocorticoid receptor DNA-binding domain susceptible to loss of function mutation.

Authors:  Jesus Banuelos; Soon Cheon Shin; Nick Z Lu
Journal:  Steroids       Date:  2015-02-09       Impact factor: 2.668

Review 6.  Disorders of sex development: update on the genetic background, terminology and risk for the development of germ cell tumors.

Authors:  Martine Cools; Leendert H J Looijenga; Katja P Wolffenbuttel; Sten L S Drop
Journal:  World J Pediatr       Date:  2009-07-09       Impact factor: 2.764

Review 7.  Different Clinical Presentations and Management in Complete Androgen Insensitivity Syndrome (CAIS).

Authors:  Lucia Lanciotti; Marta Cofini; Alberto Leonardi; Mirko Bertozzi; Laura Penta; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2019-04-09       Impact factor: 3.390

8.  Testicular histological and immunohistochemical aspects in a post-pubertal patient with 5 alpha-reductase type 2 deficiency: case report and review of the literature in a perspective of evaluation of potential fertility of these patients.

Authors:  Lavinia Vija; Sophie Ferlicot; Diana Paun; Hélène Bry-Gauillard; Gabriela Berdan; Issam Abd-Alsamad; Marc Lombès; Jacques Young
Journal:  BMC Endocr Disord       Date:  2014-05-23       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.